A year like no other: reflecting on the challenges of 2020, and looking to regain momentum for cell and gene therapy in 2021

Cell & Gene Therapy Insights 2020; 6(11), 1661–1669


Published: 8 January 2021
Peter Marks, MD, PhD

Peter Marks is the director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration. The center is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies.